Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cambrex Corp (CBM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,900,041
  • Shares Outstanding, K 33,990
  • Annual Sales, $ 490,640 K
  • Annual Income, $ 81,680 K
  • 36-Month Beta 2.12
  • Price/Sales 3.96
  • Price/Cash Flow 16.10
  • Price/Book 4.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.95 +12.61%
on 03/27/17
57.65 -2.43%
on 04/20/17
+5.80 (+11.50%)
since 03/24/17
3-Month
49.40 +13.87%
on 03/15/17
62.50 -10.00%
on 02/03/17
+2.90 (+5.44%)
since 01/24/17
52-Week
38.30 +46.87%
on 11/03/16
62.50 -10.00%
on 02/03/17
+10.75 (+23.63%)
since 04/22/16

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Cambrex After 4.38% Gain

Cambrex (NYSE:CBM) traded in a range yesterday that spanned from a low of $53.00 to a high of $55.60. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $53.35 on...

CBM : 56.25 (+0.63%)
Does Cambrex Offer a Great Value Buying Opportunity Right Now?

Value investing is easily one of the most popular ways to find great stocks in any market environment.

CBM : 56.25 (+0.63%)
Cambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017

Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that fourth quarter and full year 2016 financial...

CBM : 56.25 (+0.63%)
Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

RHHBY : 32.0100 (+1.30%)
VNDA : 14.75 (+2.08%)
CBM : 56.25 (+0.63%)
Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

RHHBY : 32.0100 (+1.30%)
VNDA : 14.75 (+2.08%)
CBM : 56.25 (+0.63%)
Momenta (MNTA) to Receive $50M Under CSL Collaboration

Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.

MYL : 37.47 (+1.74%)
NVS : 74.61 (+1.65%)
MNTA : 13.35 (+1.91%)
CBM : 56.25 (+0.63%)
Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

NVS : 74.61 (+1.65%)
RHHBY : 32.0100 (+1.30%)
REGN : 371.93 (+0.49%)
CBM : 56.25 (+0.63%)
Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

SNC : 14.71 (+1.80%)
BAK : 21.08 (+4.36%)
DQ : 18.51 (+1.09%)
ICAGY : 14.5492 (+5.35%)
CBM : 56.25 (+0.63%)
Genocea Stock Up on Positive Genital Herpes Infections Data

Genocea Biosciences, Inc. (GNCA) announced encouraging six-month data from a planned interim analysis of its ongoing placebo-controlled phase IIb study on GEN-003 for the treatment of genital herpes infections....

ANIK : 44.47 (+1.58%)
GNCA : 7.10 (+5.50%)
ARNA : 1.36 (+4.62%)
CBM : 56.25 (+0.63%)
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug

Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing...

ANIK : 44.47 (+1.58%)
ARNA : 1.36 (+4.62%)
BIIB : 276.86 (+1.44%)
CBM : 56.25 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance...

See More

Support & Resistance

2nd Resistance Point 57.68
1st Resistance Point 56.97
Last Price 56.25
1st Support Level 55.67
2nd Support Level 55.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.